New study has been conducted by ICMR or Indian Council of Medical Research to know about the effectiveness of Covaxin against the Brazilian variant of COVID-19 which is also recognized as the SARS – CoV- 2, B. 1. 128. 2. On the occasion, ICMR has collaborated with National Institute or Virology. In case of the Brazilian variant, E484K mutation has been seen that can be found in New York, United States of America also.
Earlier, a study has been done by ICMR against the UK variant that is recognized as B 1.1.7 in addition to the Indian double mutant variant B. 1.617 also. Through these studies, it has been established that the Covaxin is effective against all these coronavirus variants
Dr. Satish Chandran, Ocugen vaccine scientific advisory board chairperson has said “We are pleased to see the results of this study as it demonstrates the potential effectiveness of Covaxin against multiple variants, further strengthening our belief that this vaccine can potentially eliminate the possibility of mutant virus escape”
Covaxin in USA
Ocugen is a well known biopharmaceutical company that has its base in USA. For the US market, Ocugen has taken the responsibility to develop the Covaxin. Co-founder of Ocugen Dr. Shankar Musunuri has said “Covaxin continues to show strong results in all the studies conducted to date. We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic. The Ocugen team submitted a comprehensive drug master file to the FDA [Food and Drug Administration, USA] and is currently diligently preparing the emergency use authorisation application.”
Following to the phase 3 clinical trial, second interim result has shown that Covaxin is about 78% effective overall. However, it is believed to be 100% effective as far as the severe cases are concerned.
During a conference recently, Dr Fauci who is a pandemic expert and medical advisor to the White House has said about Covaxin “This is something where we’re still gaining data on a daily basis. But the most recent data, was looking at convalescent Sera of COVID-19 cases and people who received the vaccine used in India, the Covaxin. It was found to neutralise the 617 variants”
The New York Times has reported that Covaxin works with the motive to create antibodies against the coronavirus with the help of the immune system. Generally, antibodies attach itself with the virus protein like the spike protein.
India has been going through the second wave of coronavirus now. It is a really difficult time for the country indeed. However, they are expected to come out of this phase with the help of these vaccines.